View Cart (0 items)


Pfizer ordered to pay $45 million in menopause drug case

January 5, 2012
NEW YORK — An appeals court has ordered Pfizer Inc. to pay more than $45 million in damages to two women who claimed they developed breast cancer after taking
Read More

New Teva CEO plans to shift focus to branded drugs

January 4, 2012
ERUSALEM — Teva Pharmaceutical Industries new CEO Jeremy Levin said he plans to shift the company’s focus from generics to branded drugs, The Economic Times reported. Levin, a former
Read More

Merck to pay $24 million to settle Medicaid fraud lawsuit

December 21, 2011
BOSTON — Merck & Co. has agreed to pay $24 million to settle allegations that it overcharged the Massachusetts state Medicaid program, The Boston Globe reported. The settlement represents
Read More

Pfizer’s failed blood-cancer drug helped leukemia patients, study finds

December 15, 2011
SAN DIEGO — According to a study released Wednesday at the American Society of Hematology meeting in San Diego, Pfizer Inc.’s blood-cancer drug Mylotarg, which was pulled from shelves
Read More

FDA: Bayer must update Yaz warning labels

December 14, 2011
EAST ST. LOUIS, Mo. — An independent FDA panel has voted 21-5 to require Bayer AG to update warning labels on its popular birth control Yaz to reflect new
Read More

Pfizer elects Ian Read as chairman of the board

December 13, 2011
NEW YORK — Pfizer Inc. announced Monday that its Board of Directors has elected current President and CEO Ian Read as chairman of the board, according to a press
Read More

Merck to establish R&D headquarters in Beijing

December 6, 2011
BEIJING — Pharmaceutical company Merck & Co. announced plans to establish an Asian R&D headquarters in Beijing and commit $1.5 billion to research and development in China over the
Read More

Parents claim Zoloft caused birth defects

December 1, 2011
ST. CLAIR COUNTY, Ill. — A recently filed lawsuit against Pfizer claims the ingestion of Zoloft during pregnancy led eight different couples to parent children with various birth defects,
Read More

Onyx Pharmaceuticals considers sale

November 29, 2011
SAN FRANCISCO — Onyx Pharmaceuticals Inc., known for its kidney-cancer treatment Nexavar, is exploring options, including a possible sale, according to Bloomberg. Potential buyers are studying Onyx''s business and
Read More

Pfizer to acquire Excaliard Pharmaceuticals

November 22, 2011
NEW YORK and SAN DIEGO — Pfizer Inc. and Excaliard Pharmaceuticals, Inc. announced today that they have entered into a definitive agreement under which Pfizer will acquire Excaliard, a
Read More